Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Inclusion Criteria:

• Pathologically or cytologically confirmed diagnosis of unresectable Stage IIInon-small cell lung cancer as judged by the investigator.

• Tissue or blood samples tested and confirmed to be positive for EGFR sensitivemutation

• ECOG Performance Status of 0-1

• At least one measurable lesion according to RECIST 1.1

• Adequate organ and marrow function

Exclusion Criteria:

• Histologically or cytologically confirmed combined SCLC and NSCLC, large cellneuroendocrine carcinoma, and sarcoma-like carcinoma

• The presence of malignant pleural effusion

• Prior systemic anti-cancer therapy for non-small cell lung cancer

• Prior local radiotherapy for NSCLC

• Patients with uncontrolled gastrointestinal diseases that may affect the absorptionof test drugs (such as Crohn's disease, ulcerative colitis, absorption disorders, ordiarrhea of any cause ≥ Grade 2 CTCAE) according to the investigator's assessment